Aurobindo Pharma has informed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Monday, February 9, 2026, to consider and approve, the Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025. Further to its letter dated December 24, 2025 whereby the company has informed the closure of Trading Window of the Company from January 1, 2026 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025, the company has informed that the Trading Window will remain closed up to February 11, 2026 and shall be re-opened on February 12, 2026.
The above information is a part of company’s filings submitted to BSE.
